About
OPKO Health Inc is a multinational corporation that researches, develops, and produces a variety of pharmaceutical technologies. The company pursues diagnostics, genetic testing, cancer treatment, fertility, growth hormone deficiency, and other areas of pharmaceutical research.
OPKO Israel encompasses two main entities: OPKO Biologics and FineTech Pharmaceutical. OPKO Biologics, previously known as Prolor Biotech, is a clinical-stage company that concentrates on creating long-acting versions of therapeutic proteins and peptide drugs. They employ advanced technologies such as CTP, reversible PEGylation, and native stabilizer proteins. On the other hand, FineTech is involved in the development of high-value Active Pharmaceutical Ingredients (APIs) and devises methods to bypass patents, facilitating faster commercial progress for its pharmaceutical clients.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did OPKO Health acquire FineTech Pharmaceutical?
- OPKO Health acquired FineTech Pharmaceutical for $27.5 million in December 2011.
- What was the strategic change for Prolor Biotech in April 2014?
- In April 2014, OPKO Health transformed Prolor Biotech into its Israeli R&D and investment arm, renaming it OPKO Biologics.
- When did OPKO Health become publicly traded on NASDAQ?
- OPKO Health became public on NASDAQ in November 1995.
- When did OPKO Health become publicly traded on TASE?
- OPKO Health became public on TASE in August 2013.
- What was OPKO Health's decision regarding its TASE listing in April 2018?
- In April 2018, OPKO Health initially announced its intention to delist from the Tel Aviv Stock Exchange (TASE) but then retracted that decision later the same month.
- What was a significant development for OPKO Health in March 2020?
- In March 2020, OPKO Health announced a COVID-19 diagnostic lab, which led to a jump in its stock.
- What collaboration did OPKO Biologics announce in September 2023?
- In September 2023, OPKO Biologics announced a collaboration with Entera Bio to develop oral peptide tablet formulations for obesity and intestinal malabsorption syndromes.
- What partnership expansion did OPKO Health and Entera Bio announce in February 2026?
- In February 2026, OPKO Health and Entera Bio expanded their partnership to advance a first-in-class oral long-acting PTH tablet for patients with hypoparathyroidism.
- What is the employee count for OPKO Health in Israel?
- OPKO Health has between 51 and 200 employees in Israel, with an exact count of 59.
- What is OPKO Health's primary focus as a multinational corporation?
- OPKO Health is a multinational corporation focused on researching, developing, and producing pharmaceutical technologies, including diagnostics, genetic testing, cancer treatment, fertility, and growth hormone deficiency.